Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	316.77	196.81	29.16	99.92
Cash & Short-Term Investments	383.94	196.81	29.16	99.92
Cash Growth	156.63%	574.99%	-70.82%	-
Prepaid Expenses	6.67	4.86	4.95	6.23
Total Current Assets	391.3	201.67	34.11	106.15
Property, Plant & Equipment	26.46	29.92	34.98	41.23
Long-Term Deferred Charges	-	4.6	-	-
Other Long-Term Assets	4.3	4.35	2.41	2.58
Total Assets	422.06	240.54	71.5	149.96
Accounts Payable	2.92	1.94	2.02	1.59
Accrued Expenses	14.43	14.1	9.81	14.87
Current Portion of Leases	4.76	4.63	4.49	4.32
Total Current Liabilities	22.11	20.67	16.32	20.78
Long-Term Debt	-	-	20.08	-
Long-Term Leases	19.42	22	25.05	27.73
Other Long-Term Liabilities	1.09	0.97	-	-
Total Liabilities	42.62	43.64	61.45	48.51
Common Stock	0.05	0	0	0.02
Additional Paid-In Capital	834.3	47.24	21.84	12.79
Retained Earnings	-454.98	-358.43	-395.69	-295.27
Total Common Equity	379.44	-311.18	-373.85	-282.46
Shareholders' Equity	379.44	196.9	10.05	101.44
Total Liabilities & Equity	422.06	240.54	71.5	149.96
Total Debt	24.18	26.63	49.62	32.06
Net Cash (Debt)	359.75	170.18	-20.47	67.86
Net Cash Per Share	11.91	62.33	-8.94	33.76
Filing Date Shares Outstanding	48.12	43.8	2.32	2.01
Total Common Shares Outstanding	48.08	2.44	2.32	2.01
Working Capital	369.19	181	17.79	85.37
Book Value Per Share	7.89	-127.72	-160.95	-140.52
Tangible Book Value	379.44	-311.18	-373.85	-282.46
Tangible Book Value Per Share	7.89	-127.72	-160.95	-140.52
Machinery	-	17.31	16.47	16.08
Construction In Progress	-	0.03	0.06	-
Leasehold Improvements	-	5.45	5.36	5.33

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q